Clinical Trials

Accrual Status
Limit to SWOG Trials

1052 Results

View
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S1900F

A Randomized Phase II Study of Carboplatin and Pemetrexed with or without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)
Status Notes
Closed 6/27/2023
Research Committee(s)
LungMAP
Activated
07-25-2022
Closed
06-27-2023
ClinicalTrials.gov Registry Number
05364645
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Status Notes
Activation Date: 06/06/2022
Research Committee(s)
Gastrointestinal Cancer
Activated
06-06-2022
Closed
10-01-2024
ClinicalTrials.gov Registry Number
NCT05308446
Closed
Phase
Accrual
17%
SWOG Clinical Trial Number
S1800D

A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)
Status Notes
S1800D is permanently closed to accrual, effective March 10, 2023. This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
02-15-2022
Closed
03-10-2023
Open
Phase
Accrual
88%
SWOG Clinical Trial Number
S2012

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Status Notes
Activation: Effective December 02, 2021 at 2:00 p.m. Eastern.
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12-02-2021
ClinicalTrials.gov Registry Number
NCT05058651
Open
Phase
Accrual
69%
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10-14-2021
Closed
Phase
Accrual
3%
SWOG Clinical Trial Number
S2011

Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL
Status Notes
The study referenced above is closed to participant accrual effective November 15th, 2023, at 3:00 p.m. Eastern Time.
Research Committee(s)
Genitourinary Cancer
Activated
10-06-2021
Closed
11-15-2023
ClinicalTrials.gov Registry Number
04871529
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S1934

NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Status Notes
S1934 is permanently closed effective 3/1/2023.
Research Committee(s)
Lung Cancer
Activated
09-09-2021
Closed
03-01-2023
ClinicalTrials.gov Registry Number
04989283
Open
Phase
Accrual
73%
SWOG Clinical Trial Number
S2013

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Status Notes
Effective on 11/15/24 with Revision #6, Cohort 1 is permanently closed to accrual and Cohort 2 is open to enrollment.
Research Committee(s)
Symptom Management and Survivorship
Activated
08-16-2021
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1912CD

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Status Notes
This study will be permanently closed to new patient and caregiver accrual, effective December 16, 2024, at 12:00 p.m. Pacific Time.
Research Committee(s)
Cancer Care Delivery
Activated
07-26-2021
ClinicalTrials.gov Registry Number
NCT 04960787
Open
Phase
Accrual
40%
SWOG Clinical Trial Number
S2005

A PHASE II RANDOMIZED STUDY COMPARING IBRUTINIB AND RITUXIMAB VS. VENETOCLAX AND RITUXIMAB IN PREVIOUSLY UNTREATED WALDENSTROM'S MACROGLOBULINEMIA (WM) /LYMPHOPLASMACYTIC LYMPHOMA (LPL)
Status Notes
Re-Activation - Effective (2/15/2024)
Research Committee(s)
Myeloma
Activated
06-24-2021
ClinicalTrials.gov Registry Number
04840602
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1900E

A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Status Notes
Effective December 27, 2024 at 12:00 p.m. Pacific Time, sub-study S1900E will be permanently closed to accrual as it has met its protocol-specified accrual goal.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
04-02-2021
Closed
12-27-2024
Closed
Phase
Accrual
32%
SWOG Clinical Trial Number
S1918

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Status Notes
Effective 4/24/2026, S1918 has been permanently closed to accrual.
Research Committee(s)
Lymphoma
Activated
03-19-2021
ClinicalTrials.gov Registry Number
04799275
Closed
Phase
Accrual
72%
SWOG Clinical Trial Number
S1937

A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.
Status Notes
This study has been Permanently Closed as of 3/13/2026.
Research Committee(s)
Genitourinary Cancer
Activated
02-16-2021
Closed
03-13-2026
ClinicalTrials.gov Registry Number
NCT04579224
Closed
Phase
Accrual
64%
SWOG Clinical Trial Number
S2007

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Status Notes
Status Notes: Permanently Closed to Accrual 04/07/2025, 2:00 pm CT

Research Committee(s)
Breast Cancer
Activated
12-15-2020
Closed
04-07-2025
ClinicalTrials.gov Registry Number
04647916
Open
Phase
Accrual
84%
SWOG Clinical Trial Number
S1925

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Status Notes
Active effective 12/14/20
Research Committee(s)
Leukemia
Lymphoma
Symptom Management and Survivorship
Activated
12-14-2020
ClinicalTrials.gov Registry Number
04269902
Closed
Phase
Accrual
83%
SWOG Clinical Trial Number
S2001

Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects
Status Notes
Activation, Effective 12/04/2020, 3:00 pm eastern
Research Committee(s)
Gastrointestinal Cancer
Activated
12-04-2020
Closed
10-23-2025
ClinicalTrials.gov Registry Number
NCT04548752
Open
Phase
Accrual
48%
SWOG Clinical Trial Number
S1931

Phase III trial of Nivolumab and Ipilimumab with or without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Status Notes
Active effective 11/16/2020
Research Committee(s)
Genitourinary Cancer
Activated
11-16-2020
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Status Notes
Permanent Closure to Accrual, Effective June 18, 2024, at 3:00 PM Eastern Time
Research Committee(s)
Melanoma
Activated
09-23-2020
Closed
03-01-2026
ClinicalTrials.gov Registry Number
NCT04511013
Closed
Phase
Accrual
99%
SWOG Clinical Trial Number
S1904

Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)
Status Notes
This study is approaching the overall accrual target, therefore, it will be permanently closed to new patient accrual, effective June 14, 2024, at 12:00 p.m. PT.
Research Committee(s)
Prevention, Screening, and Surveillance
Breast Cancer
Activated
09-01-2020
ClinicalTrials.gov Registry Number
NCT 04496739
Closed
Phase
Accrual
36%
SWOG Clinical Trial Number
S1905

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Status Notes
Closed to Accrual as of 02/15/2026.
Research Committee(s)
Leukemia
Activated
08-17-2020
Closed
02-15-2026
ClinicalTrials.gov Registry Number
NCT#04315324